Kiora Pharmaceuticals Inc.
KPRX | NASDAQ
$2.68
-$0.08 (-2.90%)
At close: Sep 21, 2026, 4:00 PM ET
$2.69
+$0.01 (+0.37%)
After-hours:
Sep 21, 2026, 5:10 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 16M | n/a | n/a | n/a | 12.06K |
Cost of Revenue | 24.8K | n/a | n/a | n/a | n/a | 3.27M |
Gross Profit | -24.8K | 16M | n/a | n/a | n/a | -3.26M |
Operating Income | -9.46M | 4.51M | -12.59M | -12.31M | -14.24M | -6.87M |
Interest Income | 894K | 1.25M | 173.99K | 56.89K | 1.14K | 23.34K |
Pretax Income | -12.12M | 5.66M | -12.42M | -13.7M | -13.96M | -6.85M |
Net Income | -10.84M | 3.59M | -12.51M | -13.58M | -13.77M | -6.86M |
Selling & General & Admin | 5.75M | 5.54M | 4.66M | 8.28M | 5.32M | 4.24M |
Research & Development | 10.78M | 4.9M | 4.03M | 3.45M | 5.35M | 3.57M |
Other Expenses | -7.09M | 1.05M | 3.9M | 582.61K | 3.56M | -4.2M |
Operating Expenses | 9.43M | 11.49M | 12.59M | 12.31M | 14.24M | 3.61M |
Interest Expense | 19.96K | 21.45K | 11.13K | 8.6K | 6.85K | 4.19K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.46M | 11.49M | 12.59M | 12.31M | 14.24M | 6.88M |
Income Tax Expense | -1.28M | 2.07M | 90.32K | -113.01K | -192.6K | 12.06K |
Shares Outstanding (Basic) | 4.17M | 3.87M | 538.01K | 732.3K | 241.1K | 114.79K |
Shares Outstanding (Diluted) | 4.1M | 4.13M | 538.01K | 732.3K | 241.1K | 114.79K |
EPS (Basic) | -2.60 | 0.93 | -24.25 | -18.55 | -68 | -70.50 |
EPS (Diluted) | -2.64 | 0.87 | -24.25 | -18.55 | -68 | -70.50 |
EBITDA | -12.07M | 5.7M | -12.36M | -13.65M | -13.91M | -7.47M |
EBIT | -12.1M | 5.68M | -12.41M | -13.69M | -13.96M | -7.51M |
Depreciation & Amortization | 24.8K | 19.21K | 51.8K | 41.61K | 45.3K | 33.4K |
Add to Watchlist
Select watchlists to add or remove KPRX